Agilent Technologies Stock News

Agilent (A) delivered earnings and revenue surprises of 3.42% and 1.30%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Benzinga’s after-hours earnings roundup aims to deliver quick details about a company's earnings report, its forward-looking guidance and any other notable details. The list is handpicked by the rep

Benzingas after-hours earnings roundup aims to deliver quick details about a company''s earnings report, its forward-looking guidance and any other notable details. The list is handpicked by the reporters on the Benzinga Pro Newsdesk team. Agilent Technologies Inc (NYSE: A ) reported quarterly earnings of $1.21 per share, which beat the analyst consensus estimate of $1.03 by 17.48%. The company reported quarterly sales of $1.67 billion, which beat the analyst consensus estimate of $1.46 billion by 14.66%. Shares are 1.1% lower to $129 in after-hours trading. Mosaic Co (NYSE: MOS ) reported quarterly sales of Full story available on Benzinga.com

Agilent Technologies, Inc.'s (A) CEO Mike McMullen on Q1 2022 Results - Earnings Call Transcript

Agilent Technologies Earnings, Revenue Beat in Q1

Shares of Agilent Technologies Inc. initially were initially up 1% in extended trading Tuesday after the company reported fiscal first-quarter results that were slightly above Wall Street analysts'' forecasts. Agilent posted net income of $283 million, or 93 cents a share, compared with net income of $288 million, or 93 cents a share, in the year-ago quarter. The company recorded an adjusted earnings of $1.21 a share. Net revenue soared 8% to $1.67 billion from $1.55 billion a year ago. Agilent also offered full-year net revenue guidance of between $6.67 billion and $6.73 billion, in line with analyst estimates. Analysts surveyed by FactSet had expected net income of $1.18 a share on revenue of $1.65 billion. Agilent''s stock has slumped 18% so far this year, while the broader S&P 500 index has tumbled 10%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Agilent Technologies press release (A): Q1 Non-GAAP EPS of $1.21 beats by $0.03.Revenue of $1.67B (+7.7% Y/Y) beats by $10M.Full year revenue is expected to be in the range of

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the first quarter ended Jan. 31, 2022, an increase of 8% compared to the first quarter of 2021 and up 9% on a core(1) basis. On a GAAP basis, first-quarter net income was $283 million, or $0.93 per share. This compares with $288 million, or $0.93 per share, in the first quarter of fiscal year 2021. Non-GAAP(2) net income was $368 million, or $1.21 per share during the quarter, c

Agilent (A) delivered earnings and revenue surprises of 3.42% and 1.30%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (NYSE: A ) has outperformed the market over the past 5 years by 7.82% on an annualized basis. Buying $100 In A: 5 years ago, an investor could have purchased 1.93 shares of Agilent Technologies at the time with $100. This investment in A would have Full story available on Benzinga.com

Benzinga's after-hours earnings roundup aims to deliver quick details about a company's earnings report, its forward-looking guidance and any other notable details. The list is handpicked by the repor

SAN DIEGO--(BUSINESS WIRE)--Element Biosciences Partners with Agilent Technologies to Validate SureSelect Target Enrichment Panels on Elements AVITI System

Agilent Technologies (NYSE:A) is scheduled to announce Q1 earnings results on Tuesday, Feb. 22, after market close.The consensus EPS estimate is $1.18 (+11.3% Y/Y)

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

Agilent's (A) fiscal first-quarter results are expected to reflect strength across LSAG, ACG and DGG segments.